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Abstract
The prevalence of diabetes mellitus (DM) is growing worldwide. Prothrombotic and proinfl am-
matory states, in adjunct to endothelial dysfunction and metabolic disorders, such as hyper-
glycemia, dyslipidemia, obesity, insulin resistance, and oxidative stress, are key features of the 
accelerated atherosclerotic progression observed in patients with DM. Moreover, drug-eluting 
stents (DES) thrombosis rate was higher in DM than in non-DM patients and DM itself was 
identifi ed as an independent predictor of stent thrombosis, particularly due to the impaired 
response to dual antiplatelet therapy. The accumulating data even before the FREEDOM trial 
provided strong evidence that in patients with DM and complex coronary artery disease, coro-
nary artery bypass grafting (CABG) was superior to percutaneous coronary intervention (PCI) 
which was based on the fi rst-generation DES. The FREEDOM trial enrolled 1900 patients 
with DM and multivessel coronary artery disease treated with CABG surgery or PCI with the 
fi rst-generation DES. The patients were followed for a median 3.8 years; CABG was superior 
to PCI as it signifi cantly reduced rates of death and myocardial infarction (MI), with a higher 
rate of stroke. The benefi t of CABG was driven by differences in rates of both MI (p < 0.001) 
and death from any cause (p = 0.049). Following the FREEDOM results, patients with DM 
ought to be informed before coronary angiography about the potential survival benefi t from 
CABG for the treatment of a complex disease. However, it should be noticed that the second ge-
neration DES were associated with better outcomes compared to the fi rst-generation DES. New 
stent designs are continually being developed, with the aim of further improving the clinical 
effi cacy and the safety profi le of these devices. Therefore, although the results of the FREEDOM 
trial clearly demonstrated that CABG was superior to PCI in DM, a comparative analysis of 
the new incoming stents warrants further investigation. (Cardiol J 2013; 20, 4: 331–336)
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FREEDOM trial: A brief synopsis 
of the offi cial results
Sponsored by the National Heart, Lung, and 
Blood Institute, the Future Revascularization Eva-
luation in Patients with Diabetes Mellitus: Optimal 
Management of Multivessel Disease (FREEDOM) 
trial enrolled patients with diabetes mellitus (DM) 
and multivessel coronary artery disease (CAD) in 
a treatment with a coronary artery bypass graf-
ting (CABG) surgery or a percutaneous coronary 
intervention (PCI) with sirolimus-eluting stents 
(SES) and paclitaxel-eluting stents (PES). SES and 
PES were used exclusively in 51% and 43% of pa-
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tients, respectively, in the PCI group who actually 
underwent PCI [1]. Newer-generation stents could 
be used as long as they were FDA-approved. Dual 
antiplatelet therapy was recommended for at least 
12 months. From April 2005 through April 2010, 
a total of 32,966 patients were screened and only 
3309 were found to be trial-eligible. Out of them, 
1900 (57.4%) patients provided written informed 
consent and underwent randomization at 140 in-
ternational centers. The patients were followed for 
a minimum of 2 years (a median among survivors, 
3.8 years).
The patients’ mean age was 63.1 ± 9.1 years, 
29% were women, and 83% had  3-vessel disease. 
The primary outcome (a composite of death from 
any cause, nonfatal myocardial infarction [MI], and 
a nonfatal stroke) occurred more frequently in the 
PCI group (p = 0.005), with 5-year rates of 26.6% 
in the PCI group and 18.7% in the CABG group. 
The benefi t of CABG was driven by differences in 
rates of both MI (p < 0.001) and death from any 
cause (p = 0.049). The stroke was more frequent in 
the CABG group, with 5-year rates of 2.4% in the 
PCI group and 5.2% in the CABG group (p = 0.03). 
Most of the strokes (87%) were ischemic strokes 
and 13% were hemorrhagic. So, in patients with 
diabetes and advanced CAD, CABG was superior 
to PCI in that it signifi cantly reduced rates of death 
and MI, with a higher rate of stroke.
Diabetes mellitus: Why is cardiovascular 
disease so common and revascularization 
so challenging?
The prevalence of DM is growing worldwide. 
DM itself is the major cause of accelerated athero-
genesis leading to atherothrombosis and diabetic 
patients have a 2–4 times higher risk of cardiova-
scular disease and an up to 3 times increased risk 
of mortality compared to the non-DM population. 
In the developed countries, up to a quarter of all 
coronary revascularization procedures — either 
CABG or PCI — may involve DM patients [2–4].
Prothrombotic and proinfl ammatory states, in 
adjunct to endothelial dysfunction and metabolic 
disorders, such as hyperglycemia, dyslipidemia, 
obesity, insulin resistance, and oxidative stress, 
are key features of the accelerated atherosclerotic 
progression observed in patients with DM [5, 6]. 
The prothrombotic status is the consequence of 
multiple conditions, including increased platelet 
reactivity; increased levels of procoagulant agents 
such as fi brinogen, tissue factor, von Willebrand 
factor, platelet factor 4, factor VII; decreased con-
centrations of endogenous anticoagulants including 
protein C and antithrombin III; and impaired endo-
genous fi brinolysis secondary to elevated levels of 
plasminogen activator inhibitor-1 [7, 8]. 
Multiple mechanisms contribute to increased 
platelet aggregation in DM patients. First, hyper-
glycemia may induce the expression of the surface 
adhesion molecule P-selectin, the glycation of pla-
telet surface proteins with a consequent membrane 
fl uidity decrease and a platelet adhesion increase, 
the activation of protein kinase C, and may exert 
a direct osmotic effect [9–12]. Hyperglycemia 
may also promote atherothrombosis via oxidation 
of amino groups, formation of advanced glycation 
end-products, endothelial dysfunction, subendo-
thelial cellular proliferation, and increased matrix 
expression [12, 13]. Other abnormalities that 
contribute to the enhanced platelet adhesion and 
activation in DM include the increased expression 
of the platelet receptor glycoprotein (GP) IIb/IIIa, 
up-regulation of platelet P2Y12 receptor signalling, 
increased platelet turnover, and enhanced oxidative 
stress. In addition, insulin resistance may increase 
intracellular calcium concentration and impair the 
response to nitric oxide [9–13].
Diabetes mellitus: 
Data previous to FREEDOM
The main limitation of bare metal stents 
(BMS)-based PCI, and particularly in DM patients, 
is restenosis. A meta-analysis of 6 BMS trials, 
including 1,166 DM and 5,070 non-DM patients, 
detected a restenosis rate of 37% in DM patients 
and identifi ed DM as an independent predictor 
of restenosis (odds ratio [OR] 1.3) [14]. Even in 
the drug-eluting stents (DES) era, DM patients 
undergoing PCI have worse outcomes compared 
with non-DM individuals. Particularly, diabetic 
women who have undergone PCI are a high-risk 
group warranting special attention in treatment 
strategies [15]. Furthermore, DM patients — es-
pecially those treated with insulin — had higher 
mortality as well as stent thrombosis and target 
vessel revascularization (TVR) rates. 
A network meta-analysis of 35 randomized 
trials comparing DES with BMS and including 
3,852 DM patients showed that the use of DES, 
while not affecting overall mortality or MI rates, 
was associated with a 60–70% relative risk re-
duction in target lesion revascularization (TLR) 
depending on the type of stent used [16]. A benefi -
cial effect of DES vs. BMS in DM was confi rmed in 
a large prospective registry of consecutive patients 
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allowing for a comparison of 2 propensity-matched 
cohorts of 1476 patients each undergoing DES 
or BMS implantation. The 3-year risk-adjusted 
mortality, MI, and TVR rates in the DES vs. BMS 
propensity matched cohorts were 17.5 vs. 20.7% 
(p = 0.02), 13.8% vs. 16.9% (p = 0.02), and 18.4% 
vs. 23.7% (p < 0.001), respectively [17]. 
Most of the large-scale clinical investigations 
showed that the DES thrombosis rate was higher in 
DM than in non-DM patients and on several occa-
sions DM was identifi ed as an independent predic-
tor of stent thrombosis. This observation, together 
with the marked reduction in this complication 
associated with potent platelet inhibitors such as 
prasugrel or ticagrelor, supports the notion that the 
prothrombotic state and the impaired response to 
dual antiplatelet therapy observed in DM patients 
are of an overwhelming importance [18–21].
The accumulating evidence of PCI vs. CABG 
was pooled in a meta-analysis before the FREEDOM 
trial. Ten randomized trials with a total of 
7,812 patients were included to compare the 
effectiveness of CABG with PCI [22]. During 
a median follow-up of 5.9 years, mortality in diabetics 
after CABG (n = 615) was 23% and 29% after PCI 
(n = 618) (hazard ratio [HR] = 0.70, 95% confi -
dence interval [CI] 0.56–0.87). These data provi-
ded strong evidence that survival is substantially 
higher after CABG than PCI for the treatment of 
multivessel disease. These fi ndings were not only 
a result of the inclusion of the BARI trial since the 
trend in survival remains after exclusion of that 
trial. Six early randomized controlled trials (with 
a total of 950 diabetics) compared CABG and PCI 
[23]. In diabetic patients with multivessel CAD 
a survival advantage and fewer repeat revascu-
larization procedures were demonstrated with an 
initial surgical revascularization. However, due to 
advances in medical therapy, PCI technology, and 
surgical techniques, this conclusion was questio-
ned in the present era. More recent clinical trials 
should compare new revascularization strategies 
specifi cally in diabetic patients to defi ne the optimal 
management strategy.
The fi rst prospective randomized trial dedi-
cated to evaluate the safety and effi cacy of PCI 
compared with those of CABG in patients with 
diabetes is the Coronary Artery Revascularization 
in Diabetes trial (CARDia), which presented their 
1-year follow-up results [24]. A total of 510 diabetic 
patients with multivessel or complex single-vessel 
CAD were randomized and treated with either 
CABG or PCI using initially BMS (31%) and later 
SES (69%). The primary outcome, defined as 
a composite of all-cause mortality, MI, and stroke, 
was 10.5% in the CABG group and 13.0% in the 
PCI group (p = 0.39). The secondary outcome 
included the addition of repeat revascularization 
to the primary outcome events and did show a dif-
ference between the two groups: 11.3% for CABG 
vs. 19.3% in PCI (p = 0.02). When the patients 
who underwent CABG were compared with the 
subset of patients who received DES, the second-
ary outcome rates were comparable (12.9% and 
18.0%; HR = 1.41, 95% CI 0.82–2.42). 
Before FREEDOM, the only data from 
a randomized trial that exclusively used DES 
comes from the SYNTAX trial. It was the fi rst to 
compare a DES, in this case a PES, to CABG as 
the treatment of left main disease (isolated or in 
addition to 1-, 2-, or 3-vessel disease) or 3-vessel 
disease in a randomized controlled trial. A recent 
subgroup analysis showed 3-year outcomes of the 
trial by the treatment strategy and the subgroup 
[25]. Among this group, 452 patients were medi-
cally treated for diabetes with either hypoglycemic 
agents (59.7%) or insulin (40.3%). Patients treated 
with a diet alone were considered as nondiabetic. 
The diagnosis was made at the time of enrollment. 
Data of complete antidiabetic medication use and 
new diagnoses of diabetics after enrollment were 
unfortunately not available.
Clinical endpoints were major adverse car-
diac and cerebrovascular events (MACCE) that 
included all-cause death, stroke, MI, and repeat 
revascularization. Patient demographics and 
baseline lesion characteristics between the ran-
domized CABG and PES diabetic subgroups were 
well matched with the exception of an increased 
incidence of high triglycerides (≥ 150 mg/dL) 
in CABG compared with PES (47.1% vs. 37.0%, 
p = 0.04) and increased incidence of elevated 
blood pressure ≥ 130/85 mm Hg in PES (65.2% 
vs. 74.5%, p = 0.03) [26].
The 3-year outcome showed a significant 
increased rate of MACCE in the diabetic PES 
arm (37.0% vs. 22.9%, p = 0.002), mainly caused 
by the increased rate of repeat revascularization 
(28.0% vs. 12.9%, p < 0.001). The overall rate of 
the composite of death/stroke/MI was not signifi -
cantly different between the PES and CABG arms 
(16.3% vs. 14.0%, respectively; p = 0.527). Both 
in the non-DM and the DM subgroup, there were 
numeric increases in MI in the PES arm compared 
with the CABG arm. In the non-DM subgroup, 
this was a signifi cant difference (7.5% vs. 3.2%, 
p £ 0.001), while in the DM subgroup this did not 
reach the signifi cance (5.8% vs. 4.8%, p = 0.633). 
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Before randomization, the angiographic lesion 
complexity of coronary arteries was graded with 
the SYNTAX score [27]. There were similar results 
of the composite safety endpoint (death/stroke/
/MI) and/or repeat revascularization in the PES and 
CABG groups in the lowest SYNTAX score tertile 
(score 0–22), representing the lowest lesion com-
plexity. However, as well in the medium (SYNTAX 
score 23–32) as in the high (SYNTAX score ≥ 33) 
groups, MACCE was signifi cantly higher in the 
PES arm compared with the CABG arm: 21.0% vs. 
36.2%, p = 0.04 for the intermediate and 18.5% 
vs. 45.9%, p < 0.001 for the highest SYNTAX 
score, respectively. Furthermore, Hannan et al. 
[28] have shown that for patients with multivessel 
disease, CABG is associated with lower mortality 
rates than the treatment with DES. Therefore the 
data before FREEDOM show that in patients with 
diabetes and complex CAD, CABG was superior 
to PCI which was based on the fi rst-generation 
DES. These results are consistent with fi ndings in 
the general population; almost 1 in 7 PCI patients 
requires readmission within 30 days of a hospital 
discharge and approximately 50% of all readmitted 
PCI patients resulted in a repeat revascularization 
procedure, accompanied by a signifi cantly higher 
all-cause 30-day mortality rate [29].
Diabetes mellitus: 
Are all DES created equal?
After the FREEDOM trial there is an opinion 
[30] that the superiority of CABG over PCI on 
hard outcomes remains similar whether PCI is 
performed without stents, with BMS, or with DES. 
In the FREEDOM trial SES and PES (both are the 
fi rst-generation DES) were used as the devices of 
the same effectiveness. However, a meta-analysis 
of 5 head-to-head studies dedicated to DM patients 
(n = 1173) demonstrated that the sirolimus-eluting 
Cypher (Cordis) stent was more effective than the 
paclitaxel-eluting Taxus stent (Boston Scientifi c) 
with respect to TLR (5.1% vs. 11.4%; OR 0.41, 
p < 0.001) and angiographic binary restenosis 
(5.6% vs. 16.4%; OR 0.30, p < 0.001) [31].
Moreover, the second generation DES (e.g. 
everolimus-eluting) were associated with better 
safety outcomes compared to the fi rst-generation 
DES in patients with DM: diabetics have lower 
rates of defi nite stent thrombosis and all-cause 
mortality with second-generation everolimus-
-eluting stents (EES) rather than fi rst-generation 
DES [32]. Left main coronary artery stenting was 
also shown to be feasible and safe with excellent 
immediate and mid-term results [33], but since 
only 13.8 of the study population were diabetics, 
these promising results should not necessarily be 
extrapolated to the whole diabetic population.
In the SPIRIT V diabetic study EES was 
superior to PES for in-stent late loss at 9 months 
(0.19 mm vs. 0.39 mm, respectively; P (superiority) = 
= 0.0001). However, the composite rate of death, 
MI, and TVR was the same in the 2 groups at 1 year 
(16.3% vs. 16.4%). The authors concluded that in 
this prospective, randomized trial in a high-risk 
group of diabetic patients, implantation of EES 
compared with PES resulted in signifi cantly better 
inhibition of intimal hyperplasia with a comparab-
le safety outcome [34]. The EES compared with 
PES provided signifi cant improvements in clinical 
safety and effi cacy outcomes. The absolute benefi t 
provided by EES vs. PES appears to be proportio-
nal to the complexity of coronary disease [35]. In 
the experimental model, PES exhibited greater 
neointimal area, increased infl ammation, greater 
medial necrosis, and persistent fi brin compared 
to EES [36].
Patients from the Swedish Coronary Angio-
graphy and Angioplasty Registry (SCAAR) with 
EES had fewer adverse events than those with 
PES (HR 1.33) and signifi cantly fewer than with 
SES (HR 1.99) [32]. This was partially due to less 
stent thrombosis with EES. HRs for PES and SES 
were 1.74 and 2.87, respectively. Mortality was also 
lower with EES, with corresponding HRs of 1.69 
and 2.02 with PES and SES, respectively: an advan-
tage compatible with CABG in the FREEDOM trial.
The apparent benefi ts of EES might refl ect the 
improvements in stent design of this second-ge-
neration device. Furthermore, the newer, recently 
introduced, modern-design rapamycin-analogs or 
PES with durable bio-absorbable or polymer-free 
platforms might theoretically represent valid al-
ternatives in diabetic patients. 
From a clinical-practice point of view, many 
interventionalists are able to identify low-risk and 
high-risk patients and as a result are able to direct 
them to the most appropriate revascularization 
treatment. For this reason, some of registry data 
have shown that clinical events were similar in 
diabetic patients undergoing CABG surgery or 
PCI [37, 38]. On an individual patient level, there 
are factors such as the risk of stroke, frailty, renal 
function, pulmonary function, patient preference, 
operator experience, and other variables that go 
into making an individualized patient decision in 
the “real world” practice. What happened with 
a diabetic patient after emergency PCI of the culprit 
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lesion during acute coronary syndrome? Should 
residual lesions be treated by CABG? It should be 
particularly pointed that of nearly 33,000 patients 
who were screened for the trial only 1-tenth were 
eligible for the inclusion, of whom just 1,900 fi nally 
provided informed consent [1]!
Finally, “You can’t stop progress”, implying 
that we are unable to control development of the 
new technology [39]. New stent designs are con-
tinually being developed, with the aim of further 
improving the clinical effi cacy and the safety profi le 
of these devices [40]. In the near future it will be 
impossible again to identify differences between 
CABG and PCI based on the newest stents without 
the requirement of a new randomized trial.
Conclusions
The results of the FREEDOM trial clearly 
demonstrated that in patients with diabetes and 
multivessel CAD, CABG was superior to PCI which 
was based on the fi rst-generation DES. CABG sig-
nifi cantly reduced rates of death and MI, but was 
associated with a higher rate of stroke. Obviously, 
patients with diabetes ought to be informed before 
coronary angiography about the potential survival 
benefi t from CABG for the treatment of multives-
sel disease. In any case, it is important to pinpoint 
that the comparative analysis between CABG and 
the new PCI technologies based on the recently 
developed and the upcoming stents warrants 
further investigation and future revascularization 
evaluations.
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